U.S. Tech Hardware Stock News

If you are wondering whether Applied Industrial Technologies is priced attractively after a strong run, the starting point is to separate recent share price excitement from what the underlying valuation actually suggests. The stock last closed at US$330.90, with returns of 2.0% over the past week, 7.7% over the past month, 27.5% year to date and 41.9% over the last year, alongside a very large 3 year gain of 137.3% and a 5 year return of 287.5%. These returns have kept Applied Industrial...

Primoris Services (NYSE:PRIM) sharply cut its 2026 profit and renewables revenue guidance. The company reported persistent cost overruns and project delays in its Renewables segment. Primoris Services announced the sudden departure of its Chief Operating Officer. Multiple law firms have launched investigations following a steep share price drop. Primoris Services (NYSE:PRIM) is under pressure after a sharp reset to its 2026 earnings outlook and renewables revenue guidance, combined with the...

uniQure (NasdaqGS:QURE) reported positive initial data from its Phase I/IIa trial of AMT-260 for refractory mesial temporal lobe epilepsy. Several patients in the initial low dose cohort experienced meaningful seizure reduction, with an encouraging safety profile. This is the first clinical efficacy and safety readout for AMT-260, expanding uniQure's pipeline beyond Huntington's disease. uniQure, trading at $49.04, is drawing fresh attention as AMT-260 moves from concept to early clinical...

Talphera, Inc. ( NASDAQ:TLPH ) insiders who bought shares over the past year were rewarded handsomely last week. The...

Insiders who acquired US$611.2k worth of Sintx Technologies, Inc.'s ( NASDAQ:SINT ) stock at an average price of...

Last week, DiaMedica Therapeutics Inc. ( NASDAQ:DMAC ) insiders, who had purchased shares in the previous 12 months...

When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...

Boston Scientific’s Watchman heart device is increasingly being implanted during combined cardiac procedures instead of as a standalone treatment. This shift in medical practice has reduced standalone Watchman procedure volumes and is expected to keep revenue for the product line roughly flat through Q3 2026. The change reflects how doctors are rethinking procedure planning, with implications for Boston Scientific’s growth mix and product planning. For investors watching Boston Scientific...

Index inclusion puts TowneBank in focus TowneBank (TOWN) has been added to the S&P Banks Select Industry Index, an event that can shift how institutional investors view and access the stock. This index inclusion may influence trading activity, liquidity, and how TowneBank fits into diversified banking portfolios. See our latest analysis for TowneBank. TowneBank’s recent index inclusion comes on the back of steady share price momentum, with a 90 day share price return of 6.76% and a 1 year...

Zeta Global Holdings (NYSE:ZETA) has entered into a partnership with Palantir Technologies to build a unified enterprise AI infrastructure layer for marketing. The collaboration centers on rearchitecting Zeta’s Data Cloud on Palantir’s Foundry platform and integrating Zeta’s Athena AI to support real-time marketing decisions. Both companies point to the potential for this integration to support new revenue streams tied to large enterprise marketing use cases. Zeta Global Holdings comes into...

How NetApp’s Valuation Fits Into a Long Term View Before weighing any valuation method, it helps to place NetApp in a broader investing context so that the numbers you are about to see fit into a bigger picture. Instead of thinking about valuation as a single answer, consider it as a set of lenses that can highlight different strengths and weaknesses of the stock. Why Valuation Matters For NetApp Stock Valuation is ultimately about what you are paying today compared with what the business may...

Iovance Biotherapeutics (NasdaqGM: IOVA) received conditional approval in Australia for Amtagvi, its T-cell therapy for advanced melanoma. The Therapeutic Goods Administration decision marks the third marketing authorization for Amtagvi after the US and Canada. Amtagvi becomes the first approved solid tumor T-cell therapy in the Australian market and is supported by an Australian treatment center. Iovance Biotherapeutics focuses on cell therapies that use a patient's own T cells to target...

If you are wondering whether Synopsys stock is priced attractively or already baking in high expectations, this valuation breakdown is designed to give you a clear and structured view. Recently, the share price closed at US$461.50, with a 2.9% gain over the past week, but a decline of 12.1% over the last month and 3.9% so far this year, including a 3.6% decline over the past 12 months. These mixed returns have kept Synopsys in focus as investors weigh long term prospects against current...

Crypto and blockchain stocks sit at the crossroads of finance and technology at a time when inflation trends, interest rate decisions and energy prices are pulling markets in different directions. With mixed signals across major economies and central banks reassessing policy paths, many investors are looking for exposure to themes that are tied to long term structural change rather than short term data noise. This Top Cryptocurrency and Blockchain Stocks screener filters the broader market to...

Earlier in June 2026, Cullinan Therapeutics reported updated Phase 1 data showing its bispecific T cell engagers CLN-978 and velinotamig produced strong clinical responses and favorable safety in heavily pre-treated rheumatoid arthritis and systemic lupus erythematosus patients, including remissions and complete renal responses in lupus nephritis. By positioning T cell engagers as off-the-shelf “immune reset” therapies across multiple autoimmune conditions, Cullinan is expanding its...

The Morning Bull - US Market Morning Update Wednesday, Jun, 24 2026 US stock futures are pointing lower this morning, with E mini S&P 500 contracts down about 1.5% and Nasdaq 100 futures off roughly 2.8%, as investors weigh weaker global growth signals against a firm interest rate backdrop. Across Europe, key business surveys such as the Euro Area composite PMI sit below 50 at 49.5, which means private sector activity is still shrinking, while UK services have slipped further into contraction...

Western Midstream Partners, LP recently filed an omnibus shelf registration covering common and preferred units and Western Midstream Operating, LP debt securities, and its subsidiary priced a US$700,000,000 offering of 5.7% senior notes due 2036 to repay borrowings and fund capital expenditures. A second produced-water treatment pilot facility in Reeves County, Texas, built with Chevron, ConocoPhillips, Devon, and ExxonMobil, significantly expands Western Midstream’s reclaimed freshwater...

Keel Infrastructure (KEEL) is back in focus after investors reacted to new government backed project wins and a multi year contracts pipeline that has pushed trading volumes higher and highlighted its AI infrastructure ambitions. See our latest analysis for Keel Infrastructure. Keel Infrastructure’s share price has been on a strong run, with a 30 day share price return of 30.77% and a 90 day share price return of 184.62%. Its 1 year total shareholder return is about 7x, reflecting rising...

Quantum computing has moved from theory to policy priority, and the latest US executive orders on quantum adoption and quantum-resistant encryption put that shift in sharp focus. With plans for a national lab-based quantum computer by 2028, plus federal grants and funding streams tied to the CHIPS and Science Act, stocks exposed to this news, such as D-Wave Quantum, are firmly on investors’ radar. This article walks through 3 stocks from our Quantum Computing Stocks With US Government Growth...

Recent Performance Snapshot for USA Compression Partners USA Compression Partners (USAC) has drawn fresh attention after a recent move in its unit price, with the stock up 2.7% over the past day and 2.0% over the past week. Despite that short term uptick, units are down about 9.7% over the past month and 7.0% over the past 3 months, which may prompt investors to reassess how current pricing lines up with the partnership’s fundamentals. See our latest analysis for USA Compression Partners. Set...

In June 2026, ZenaTech, Inc. unveiled Zoo Office, an AI-powered unified productivity platform intended to become the core foundation and brand for its Enterprise SaaS ecosystem, initially rolling out via a private beta targeting small and medium-sized businesses. The Zoo Office roadmap is distinctive because it aims to combine agentic AI, core productivity tools, and industry-specific applications into a single connected platform that reduces subscription sprawl and fragmented workflows. We...

Penny stocks usually live or die on one thing, cash. In a world where growth signals are mixed across Europe, the UK, North America and Asia, and where energy prices, inflation and policy decisions can shift sentiment quickly, having a solid balance sheet matters even more for smaller companies. The Elite Penny Stocks screener focuses on stocks that still trade at penny levels but have the financial strength to keep funding their plans. In this article, you will see 3 of the best stocks from...

In recent days, Home BancShares reported strong financial health, with year-over-year growth in both revenue and net profit and high industry rankings. At the same time, institutional ownership climbed and technical indicators strengthened, highlighting rising professional investor interest alongside robust operating efficiency. We will now examine how this improving institutional support might influence Home BancShares’ existing investment narrative and future positioning. We've uncovered...

Violent swings in US Treasury yields are rippling across markets, reshaping funding costs, bond valuations, and liquidity for companies that lean heavily on government debt markets. When borrowing costs jump and trading conditions turn choppy, some stocks can struggle with squeezed margins, pressured client activity, or balance sheets that are more exposed than they look at first glance. This article focuses on the risks, not the potential winners. It does this by breaking down 3 stocks from...